Biomm S.A.

São Paulo Stock Exchange BIOM3.SA

Biomm S.A. Capital Expenditure for the year ending December 31, 2023: USD -1.28 M

Biomm S.A. Capital Expenditure is USD -1.28 M for the year ending December 31, 2023, a -24.90% change year over year. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).

Biomm S.A. Capital Expenditure for the year ending December 31, 2022 was USD -1.02 M, a 23.12% change year over year.
Biomm S.A. Capital Expenditure for the year ending December 31, 2021 was USD -1.33 M, a -49.95% change year over year.
Biomm S.A. Capital Expenditure for the year ending December 31, 2020 was USD -888.85 K, a 51.34% change year over year.
Biomm S.A. Capital Expenditure for the year ending December 31, 2019 was USD -1.83 M, a -520.21% change year over year.

Key data

Date	Capital Expenditure	Free Cash Flow	Depreciation And Amortization	Deferred Income Tax

São Paulo Stock Exchange: BIOM3.SA

Biomm S.A.

CEO	Mr. Heraldo Carvalho Marchezini
IPO Date	Jan. 11, 2000
Location	Brazil
Headquarters	Rua dos Pinheiros, 610
Employees	130
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Biomm S.A. operates as a biotechnology company in Brazil. It offers AFREZZA, a human insulin inhalation powder; CONFORT CARE, a moisturizing foot cream; GLARGILIN, a glargine insulin; and HERZUMA, a trastuzumab. Biomm S.A. was founded in 2001 and is based in São Paulo, Brazil.

Key trends

Past 5 years